EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)
Oncology Letters · 02.06.2025 · 30 (2) · 1-11
DOI: 10.3892/ol.2025.15121 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Letters, online erschienen am 02.06.2025. Verfasst von Zhe Tian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Life Science and Clinical Medicine Research Center, Affiliated Hospital of Youjiang Medical Unive…. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Mutations in EGFR (mEGFRs) in non-small cell lung cancer (NSCLC) are key factors driving tumor development and treatment response. The present article aimed to review the classification, characteristics and molecular mechanisms of resistance to third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) associated with mEGFRs. Activating mutations (such as L858R and exon 19 deletions) are the primary markers of sensitivity to EGFR-TKIs, while rare mutations (such as G719X and S768I) require individualized treatment strategies. Resistance mechanisms are categorized into EGFR-dependent (such as T790M and C797S mutations) and -independent (bypassing signaling activation, epithelial-mesenchymal transition, tumor microenvironment remodeling and epigenetic regulation). Third-generation EGFR-TKIs (such as osimertinib) markedly improve patient survival by selectively targeting the T790M mutation, but novel resistance mutations, such as C797S, limit their long-term efficacy. Combination therapies (such as MET proto-oncogene, receptor tyrosine kinase/EGFR dual-target inhibitors) and fourth-generation TKIs (such as BLU-945) offer novel directions to overcome resistance. Future research should focus on precise subtyping, dynamic monitoring of resistance mechanisms and regulation of the immune microenvironment to advance personalized treatment for NSCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Life Science and Clinical Medicine Research Center, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi Zhuang Autonomous Region 53300…
- Department of Infectious Disease, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China.
Zitieren
APA
Tian, Z., Cen, L., Wei, F., Dong, J., Huang, Y., Han, Y., Wang, Z., Deng, J., & Jiang, Y. (2025). EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review). Oncology Letters, 30(2), 1-11. https://doi.org/10.3892/ol.2025.15121
Vancouver
Tian Z, Cen L, Wei F, Dong J, Huang Y, Han Y, et al. EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review). Oncology Letters. 2025;30(2):1-11. doi:10.3892/ol.2025.15121
BibTeX
@article{Tian2025,
author = {Tian, Zhe and Cen, Lilan and Wei, Feng and Dong, Jue and Huang, Yulan and Han, Yi and Wang, Zhibo and Deng, Junhua and Jiang, Yujie},
title = {EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)},
journal = {Oncology Letters},
year = {2025},
volume = {30},
number = {2},
pages = {1--11},
doi = {10.3892/ol.2025.15121}
}
EUVIMED